TNTuija H. Nieminen

Tuija H. Nieminen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tuija H. Nieminen has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Kari Laine

    Department of Pharmacology, Drug Development & Therapeutics, University of Turku, Turku, Finland

    4 shared publications
  • Klaus T. Olkkola

    Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University Hospital and University of Turku, Turku, Finland

    4 shared publications
  • Mikko Neuvonen

    Department of Clinical Pharmacology University of Helsinki Helsinki Finland

    4 shared publications
  • Nora M. Hagelberg

    Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University Hospital and University of Turku, Turku, Finland

    4 shared publications
  • Pertti J. Neuvonen

    Department of Clinical Pharmacology and HUSLab, University of Helsinki, Helsinki, Finland

    4 shared publications
  • Teijo I. Saari

    Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University Hospital and University of Turku, Turku, Finland

    4 shared publications

Latest Publications

  • Grapefruit Juice Enhances the Exposure to Oral Oxycodone

    by Tuija H. Nieminen, Nora M. Hagelberg, Teijo I. Saari, Mikko Neuvonen, Pertti J. Neuvonen, Kari Laine, Klaus T. Olkkola

    Abstract: Grapefruit juice alters the concentrations of many CYP3A substrates. The objective of this study was to examine the effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of oral oxycodone in a randomized cross‐over study with two phases at an interval of 4 weeks. Twelve healthy volunteers ingested 200 ml of grapefruit juice or water t.i.d. for 5 days. An oral dose of oxycodone hydrochloride 10 mg was administered on day 4. Oxycodone, noroxycodone, oxymorphone and noroxymorphone concentrations were analysed from the plasma samples for 48 hr and behavioural and analgesic effects were recorded for 12 hr. Grapefruit juice increased the mean area under the oxycodone concentration–time curve (AUC0–∞) by 1.7‐fold (p < 0.001), the peak plasma concentration by 1.5‐fold (p < 0.001) and the half‐life of oxycodone by 1.2‐fold (p < 0.001) as compared to the water. The metabolite‐to‐parent AUC0–∞ratios (AUCm/AUCp) of noroxycodone and noroxymorphone decreased by 44% (p < 0.001) and 45% (p < 0.001), respectively. Oxymorphone AUC0–∞increased by 1.6‐fold (p < 0.01) after grapefruit juice, but the AUCm/AUCpremained unchanged. Pharmacodynamic changes were modest and only self‐reported performance significantly impaired after grapefruit juice. Analgesic effects were not influenced. Grapefruit juice inhibited the CYP3A4‐mediated first‐pass metabolism of oxycodone, decreased the formation of noroxycodone and noroxymorphone and increased that of oxymorphone. We conclude that dietary consumption of grapefruit products may increase the concentrations and effects of oxycodone in clinical use.


  • St John's wort greatly reduces the concentrations of oral oxycodone

    by Tuija H. Nieminen, Nora M. Hagelberg, Teijo I. Saari, Mikko Neuvonen, Kari Laine, Pertti J. Neuvonen, Klaus T. Olkkola

    Background: Chronic pain is associated with depression. Self‐treatment of depression with herbal over‐the‐counter medicine St John's wort makes pain patients prone to drug interactions.Aims: The aim of this study was to assess the potential of St John's wort to alter the CYP3A‐mediated metabolism of a μ‐opioid receptor agonist, oxycodone.Methods: The study design was placebo‐controlled, randomized, cross‐over with two phases at intervals of 4 weeks and was conducted with 12 healthy participants. St John's wort (Jarsin®) or placebo was administered t.i.d. for 15 days and oral oxycodone hydrochloride 15 mg on day 14. Oxycodone pharmacokinetics and pharmacodynamics were compared after St John's wort or placebo. Behavioural and analgesic effects were assessed with subjective visual analogue scales and cold pressor test. Plasma drug concentrations were measured from 0 to 48 h, behavioural and analgesic effects from 0 to 12 h.Results: Following St John's wort administration the oxycodone AUC decreased 50% (p < 0.001). Oxycodone elimination half‐life shortened from a mean ± SD 3.8 ± 0.7 to 3.0 ± 0.4 h (p < 0.001). The self‐reported drug effect of oxycodone as measured by AUEC0–12 decreased significantly (p = 0.004). Differences between St John's wort and placebo phases in cold pain threshold and intensity AUEC0–12 were not observed.Conclusions: St John's wort greatly reduced the plasma concentrations of oral oxycodone. The self‐reported drug effect of oxycodone decreased significantly. This interaction may potentially be of some clinical significance when treating patients with chronic pain.


  • Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir

    by Tuija H. Nieminen, Nora M. Hagelberg, Teijo I. Saari, Mikko Neuvonen, Pertti J. Neuvonen, Kari Laine, Klaus T. Olkkola

    This study aimed to investigate the effect of antivirals ritonavir and lopinavir/ritonavir on the pharmacokinetics and pharmacodynamics of oral oxycodone, a widely used opioid receptor agonist used in the treatment of moderate to severe pain.


  • Rifampin Greatly Reduces the Plasma Concentrations of Intravenous and Oral Oxycodone

    by Tuija H. Nieminen, Nora M. Hagelberg, Teijo I. Saari, Antti Pertovaara, Mikko Neuvonen, Kari Laine, Pertti J. Neuvonen, Klaus T. Olkkola

    OXYCODONE is a semisynthetic opioid receptor agonist widely used in the treatment of acute and chronic pain.1 It has relatively high oral bioavailability of 60–80%,2 and it is mainly metabolized in the liver by cytochrome P450 (CYP) enzymes. CYP3A-mediated N -demethylation to noroxycodone accounts for the major part of its oxidative metabolism. A smaller fraction of oxycodone is O -demethylated to oxymorphone by CYP2D6. Both noroxycodone and oxymorphone are then further metabolized to noroxymorphone by CYP3A and CYP2D6.3,4 While the oxidative metabolites are responsible for 50% of the urinary excretion, the reduced metabolites in total account for approximately 18% of the dose.4 Less than 10% of the dose is excreted unchanged in the urine.2,5,6 Although the metabolites show variable pharmacologic activity, it is the parent oxycodone that seems to be responsible for the central effects of oxycodone.4